Some breaking news today: President Trump announced on Truth Social this morning that he will nominate Heidi Overton as the next FDA commissioner. The nomination is subject to Senate confirmation.
The role has been vacant since Marty Makary resigned in May. Kyle Diamantas has served as acting commissioner since then, and several other senior FDA positions also remain without permanent leadership.
A senior administration official indicated more appointments should follow.
Who Heidi Overton is
Overton is deputy director of the White House Domestic Policy Council, where she’s led health policy work since the start of the term. Before joining the administration, she was chief policy officer and vice chair of the Center for a Healthy America at the America First Policy Institute.
Her clinical and research credentials are substantial. She earned her medical degree from the University of New Mexico School of Medicine and a PhD in clinical investigation from the Johns Hopkins Bloomberg School of Public Health, where she also completed a general surgery residency. She’s board-certified in public health and general preventive medicine, and she served as a White House Fellow from 2019 to 2021.
What she does not seem to have is a record of running a large organization, which is the point we’d expect most likely to surface in hearings.
A few things that stand out to us
From what we know so far:
She’s reportedly not the first choice. Reporting from NBC News and CNN indicates the White House ran a months-long search and was still interviewing candidates as recently as Tuesday. Former Representative Brad Wenstrup declined the job. So did Diamantas, the acting commissioner, citing young children and other personal reasons.
The policy background might cut both ways. Overton’s time on the Domestic Policy Council should help with stakeholder management. She likely knows how the White House thinks and how to work the relationships that surround the agency. But some might see that same background also making her among the most politically oriented commissioner nominees in the agency’s history. Most prior nominees had extensive medical and organizational leadership records. Overton’s path seems to have run through policy rather than through running large institutions.
Expect questions about leadership experience. Makary faced them, and Overton likely will too, along with questions about whether the agency would make decisions on political rather than scientific grounds. Those are the lines of questioning worth watching in confirmation hearings.
Continuity is the reasonable assumption for now. Nothing in her record we can see suggests a sharp break from Makary’s policy direction, and the choice of a politically connected insider signals the White House wants someone who can balance stakeholder demands rather than undertake some big reset of the agenda.
The device industry's response seems positive. AdvaMed came out in support quickly, with Whitaker emphasizing the priority of keeping “transparency, consistency, and predictability” as hallmarks of CDRH review. That framing tells you what the medtech sector might be watching for!
What this means for regulated companies
Practically, not much changes tomorrow. Confirmation takes time of course, and the agency continues operating under interim leadership.
What’s maybe worth tracking now is whether the priorities set over the past year hold going forward. The FDA has spent much of that time managing itself amid workforce reductions (and, recently, on the food side, outbreak response) while advancing new guidance on AI, submissions, and inspections.
A commissioner with strong White House ties may have more success protecting agency resources than one without them.
We’ll follow this as the nomination moves forward. In the meantime, here are some non-paywalled reports on the nomination that bring more insight into the nomination:
Trump taps White House aide Overton as next FDA commissioner / Fierce Biotech
Trump nominates policy aide Dr. Heidi Overton as next FDA commissioner / CBS News
Who is The FDA Group?
The FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus on Quality Assurance, Regulatory Affairs, and Clinical Operations.
With thousands of resources worldwide, hundreds of whom are former FDA, we meet your precise resourcing needs through a fast, convenient talent selection process supported by a Total Quality Guarantee. Learn more and schedule a call with us to see if we’re a fit to help you access specialized professionals and execute your projects on time and on budget.